

## *REMARKS*

### **Specification and Claim Amendments**

The specification has been amended to provide notice of federally sponsored research and development. Claim 1 was amended to specifically describe chemotherapeutic agents as those agents selected from a group consisting of mitoxantrone, cisplatin, epirubicin and Gemzar. This amendment is supported in the disclosure as originally filed on Page 16, lines 11-16 and 28-29, and Page 17, lines 12-21. Claim 1 was also amended to specifically describe the oligonucleotide of SEQ ID NO: 1. This amendment is supported in the disclosure as originally filed on Page 5, line 13. In addition, claims 2 and 21 were amended to more clearly describe the invention. Furthermore, claims 9-16, 19-20 and 22 were canceled. No new matter is added by way of these amendments.

### **Office Action**

The Office Action alleges that claims 1-9 and 12-23 lack enablement under §112 because the specification does not enable chemosensitizing with *any* oligonucleotide and *any* chemotherapeutic agent. The Office Action, however, maintains that the specification enables chemosensitization with an oligonucleotide (SEQ ID NO: 1) in combination with mitoxantrone, cisplatin, epirubicin or Gemzar.

### **Discussion of Enablement Rejection Under Section 112**

As amended, the present invention claims chemosensitization with specific chemotherapeutic agents, namely mitoxantrone, cisplatin, epirubicin and Gemzar in combination with an oligonucleotide having the sequence of SEQ ID NO:1. Accordingly, the present invention is enabled in accordance with §112.

In re Appln. of Kasid et al.  
Application No. 10/075,994

### Conclusion

The application is considered in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



M. Daniel Hefner, Reg. No. 41,826  
LEYDIG, VOIT & MAYER, LTD.  
Two Prudential Plaza, Suite 4900  
180 North Stetson Avenue  
Chicago, Illinois 60601-6780  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: May 18, 2005